Company intelligence / Profile preview

CellSave Arabia

Dubai, Dubai, United Arab Emirates

Ownership: Private
Employees: ~60
Development stage: Other

Overview

CellSave Arabia is the GCC’s first and largest commercial private stem cell bank, part of CSG.BIO Group. It has commercialized advanced cord blood and stem cell banking, with more than 750,000 units preserved and over 665 therapeutic releases (including both established and experimental treatments) for various blood disorders, cancer, and regenerative indications in the GCC region and globally, maintaining industry-leading accreditations (AABB, US FDA, UAE MOH, DHA, and DHCC).

Therapeutic areas: HematologyImmunologyOtherWomen's HealthNeurologyDermatologyOncologyMen's Health
Modalities: Cell therapyStem cell therapyRegenerative medicine
Industry: Non-Drug Biotech

Partnerships

Abu Dhabi Stem Cell Centre (ADSCC)

Beyond the preview

Go deeper on CellSave Arabia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellSave Arabia.

Explore the full profile